Looking to buy CJC 1295 without DAC and Ipamorelin online for your laboratory setup? PX1 Research provides analytical-grade research peptides with batch-specific third-party Certificate of Analysis (COA) verification, guaranteeing high purity (>99%) and documented endotoxin testing. Every lot is manufactured in US-based GMP-compliant facilities strictly for in vitro and preclinical research applications.
Looking to buy CJC 1295 without DAC and Ipamorelin online for your laboratory setup? PX1 Research provides analytical-grade research peptides with batch-specific third-party Certificate of Analysis (COA) verification, guaranteeing high purity (>99%) and documented endotoxin testing. Every lot is manufactured in US-based GMP-compliant facilities strictly for in vitro and preclinical research applications.
To buy CJC 1295 without DAC and Ipamorelin online for preclinical research, institutional investigators require verifiable purity, analytical documentation, and lot-to-lot consistency. CJC-1295 without DAC (also known as Modified GRF 1-29) combined with Ipamorelin represents a complementary dual-peptide system designed to evaluate synergistic growth hormone secretagogue signaling in cell culture and animal models. Obtaining these compounds from a certified domestic manufacturer ensures structural fidelity and eliminates potential contamination risks common in unverified imports.
PX1 Research supplies analytical-grade CJC-1295 without DAC and Ipamorelin synthesized via automated solid-phase peptide synthesis (SPPS). Each lot undergoes rigorous testing, including high-performance liquid chromatography (HPLC) to verify chemical purity and mass spectrometry (MS) to confirm sequence identity. Researchers can review complete batch analytical records across our catalog of research peptides to ensure experimental repeatability.
CJC-1295 without DAC is a 29-amino-acid synthetic peptide analog of endogenous growth-hormone-releasing hormone (GHRH). By substituting specific amino acids at positions 2, 8, 15, and 27 (D-Ala2, Gln8, Ala15, and Leu27), the peptide exhibits enhanced resistance to enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) compared to native GHRH(1-29). Unlike CJC-1295 with DAC (Drug Affinity Complex), the non-DAC variant does not bind covalently to serum albumin, resulting in a significantly shorter biological half-life (~30 minutes) that replicates the natural, pulsatile secretion pattern of GHRH in mammalian models.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) engineered as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Unlike earlier growth hormone-releasing peptides (GHRPs), Ipamorelin exhibits extreme selectivity for GH release without stimulating adrenocorticotropic hormone (ACTH), cortisol, or prolactin secretion in rodent models. When researchers evaluate a combined formulation, such as a CJC-1295 No DAC / Ipamorelin blend, they examine how concurrent activation of GHRH and GHS-R pathways alters intracellular signaling cascades.
The primary objective of co-administering GHRH analogs and GHRP agonists in laboratory studies is to observe receptor cross-talk and synergistic GH release. CJC-1295 No DAC binds directly to the GHRH receptor (a G-protein coupled receptor) on somatotroph cells in the anterior pituitary. This binding activates adenylate cyclase, raising intracellular cyclic adenosine monophosphate (cAMP) levels and protein kinase A (PKA) activity, which stimulates growth hormone gene transcription and exocytosis.
Concurrently, Ipamorelin binds to GHS-R1a, triggering the phospholipase C (PLC) pathway. This results in the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), causing a transient influx of intracellular calcium (Ca2+) from endoplasmic reticulum stores. The simultaneous activation of the cAMP/PKA path via GHRH receptors and the IP3/Ca2+ path via GHS-R1a produces a amplified secretory response—releasing more growth hormone than the mathematical sum of either peptide administered independently in preclinical assays.
In vitro assays and rodent models have demonstrated that CJC-1295 without DAC facilitates sustained pulsatile GH secretion while preserving the natural feedback loops mediated by somatostatin. Preclinical studies suggest that maintaining normal GH pulsatility, rather than continuous tonic elevation, helps prevent receptor downregulation and desensitization over extended research protocols. Downstream observation in laboratory models routinely reports elevated circulating insulin-like growth factor 1 (IGF-1) levels, which mediate cellular proliferation, extracellular matrix remodeling, and metabolic substrate partitioning.
Research focusing on musculoskeletal tissue repair indicates that downstream IGF-1 upregulation supports collagen synthesis, satellite cell activation in skeletal muscle assays, and osteoblast differentiation in bone marrow stromal cell cultures. Detailed biological dynamics and pathway diagrams are documented in our GHRH and GHRP Synergy Preclinical Review section.
When designing secretagogue research protocols, selecting the appropriate peptide class depends on the specific physiological markers under investigation. Compared to other compounds in the GHRH and GHRP categories, the combination of CJC-1295 No DAC and Ipamorelin offers distinct receptor selectivity and kinetic profiles. Researchers comparing alternative candidates often review the following options within our research library hub:
While Sermorelin acts as a native-sequence GHRH(1-29) truncated peptide, it possesses a shorter half-life (~10-12 minutes) due to rapid DPP-IV cleavage, requiring higher molar concentrations in vitro compared to CJC-1295 No DAC. In contrast, older GHRPs such as GHRP-2 and Hexarelin demonstrate potent GH release via GHS-R1a but induce non-selective elevations in systemic cortisol and prolactin levels in animal models. Ipamorelin remains the preferred GHS-R agonist for selective studies due to its minimal impact on secondary endocrine axes.
Proper handling and reconstitution procedures are essential to maintain peptide integrity and ensure reproducible assay outcomes. CJC-1295 without DAC and Ipamorelin are supplied as lyophilized (freeze-dried) cakes in sterile glass vials. Lyophilized peptides should be stored in a controlled freezer environment at -20°C or -80°C upon receipt to prevent hydrolytic degradation.
For laboratory reconstitution, researchers should use bacteriostatic water (0.9% benzyl alcohol preserved) or sterile deionized water, depending on the downstream cellular assay requirements. The diluent should be introduced slowly along the inner glass wall of the vial to minimize shear force and foam formation. Gentle swirling is recommended; aggressive vortexing can disrupt delicate secondary peptide structures. Once reconstituted, solution aliquots should be stored at 2°C to 8°C and used within defined experimental windows to avoid peptide oxidation or aggregation.
The analytical validity of preclinical research depends entirely on the purity and identity of the reagents used. Substandard or impractically impure peptides introduce unknown variable contaminants that can invalidate cell viability assays or distort receptor-binding kinetics. PX1 Research enforces strict quality assurance metrics for every production lot:
Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is performed to verify that target peptide purity meets or exceeds 99.0%. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the precise molecular mass and amino acid sequence identity. Furthermore, because bacterial lipopolysaccharides (endotoxins) can trigger inflammatory cascades in cell culture and animal models, every batch undergoes Chromogenic LAL Endotoxin Testing to ensure levels fall strictly below standard research safety thresholds (<0.01 EU/μg).
When purchasing peptides online, analytical transparency and supply chain traceability are critical for institutional labs and corporate research entities. PX1 Research operates out of state-of-the-art facilities located in California and Arizona. All manufacturing processes follow standard Good Manufacturing Practice (GMP) guidelines, and final analytical verification is performed by independent ISO 17025 accredited testing laboratories.
We support research universities, biotechnology firms, and contract research organizations (CROs) with comprehensive documentation, including batch-specific COAs, mass spectra, and HPLC chromatograms. For high-volume investigative programs or custom synthesis needs, institutional procurement teams can utilize our wholesale lab account portal to access bulk pricing, lot-reservation options, and dedicated account management.
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295 with DAC contains a Drug Affinity Complex that covalently binds to circulating serum albumin, extending its biological half-life to several days and producing continuous GH elevation. CJC-1295 without DAC (Mod GRF 1-29) lacks this complex, resulting in a half-life of ~30 minutes that replicates physiological pulsatile GH release in animal models.
Why are CJC-1295 No DAC and Ipamorelin frequently studied together?
CJC-1295 No DAC targets the GHRH receptor to elevate intracellular cAMP, while Ipamorelin targets the GHS-R1a receptor to elevate intracellular calcium. In preclinical studies, activating both signal transduction pathways simultaneously produces a synergistic increase in growth hormone secretion far greater than either compound alone.
How can I verify the purity of CJC-1295 No DAC and Ipamorelin from PX1 Research?
Every product lot is supplied with a downloadable, batch-specific Certificate of Analysis (COA). Purity is verified using RP-HPLC (>99% pure target), molecular mass is confirmed via Mass Spectrometry, and safety for cell models is verified via Chromogenic LAL Endotoxin Testing.
What solvent should be used for reconstituting CJC-1295 No DAC and Ipamorelin vials?
For standard laboratory handling and multi-dose research protocols, bacteriostatic water (0.9% benzyl alcohol) is typically used. For sensitive in vitro cell culture applications where preservatives might interfere with cell viability, sterile 0.9% saline or sterile water for injection is preferred.
How should reconstituted peptide solutions be stored in the lab?
Reconstituted liquid solutions should be stored under refrigeration at 2°C to 8°C (36°F to 46°F) and kept away from direct light. Aliquoting the solution prior to freezing can help prevent repeated freeze-thaw cycles if long-term storage is necessary.
Does Ipamorelin stimulate cortisol or prolactin secretion in preclinical models?
Unlike older secretagogues such as GHRP-2 or GHRP-6, preclinical literature demonstrates that Ipamorelin is highly selective for GHS-R1a and does not cause statistically significant elevations in ACTH, cortisol, or prolactin levels in animal models.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research peptides are manufactured in US-based GMP-compliant facilities and shipped directly from our primary fulfillment hubs in California and Arizona. Orders placed Monday through Friday before cut-off times ship same-day.
Are CJC-1295 No DAC and Ipamorelin approved for human use or clinical administration?
No. CJC-1295 No DAC and Ipamorelin are sold exclusively as research chemicals for in vitro laboratory research, analytical testing, and preclinical animal studies. They are strictly not for human consumption, therapeutic use, or clinical trials.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.